Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Life Sciences
Novel Heterocyclic Arylidene Derivatives As Anticancer Agents Against U87 Human Glioblastoma, Benjamin H. Hiramoto
Novel Heterocyclic Arylidene Derivatives As Anticancer Agents Against U87 Human Glioblastoma, Benjamin H. Hiramoto
Honors Theses
The primary objectives of this interdisciplinary study were the synthesis of novel heterocyclic arylidenes and the investigation of their anticancer activity against U87 glioblastoma cell viability. Recently, novel hybrid derivatives have been considered as potential candidates for treating glioblastoma, demonstrating a synergistic anticancer effect in previous studies. 12 heterocyclic arylidenes with various functional groups, including halogens and boronic acid, were produced via a Knoevenagel condensation. These compounds and their starting reagents were then administered to U87 glioblastoma cancer cells at graded concentrations within a 12-well cell viability assay to determine each compound’s lethal concentration 50 (LC50). The LC50 of each …
Synthesis Of An Arylidene Pyrazolone And Its Effects On Glioblastoma Cancer Cells, Joanna Deonarine
Synthesis Of An Arylidene Pyrazolone And Its Effects On Glioblastoma Cancer Cells, Joanna Deonarine
Honors Theses
The purpose of this research is to develop a new technique to synthesize a heterocyclic arylidene compound using fruit puree catalysis and investigate its anti-cancer activity on glioblastoma cancer cells. Recently, there has been interest in heterocycles due to their anticancer properties and they have been used in almost two-thirds of the novel molecular anticancer agents. Varying fruit purees were used to synthesize a novel hybrid arylidene pyrazolone from 3-methyl-1-phenyl-5-pyrazolone and 4-dimethylaminobenzaldehyde by modifying methodology developed by Dr. Murray. This arylidene pyrazolone was then tested for its anticancer activity on glioblastoma brain cancer cells using Dr. Smith’s 12-well cell viability …